Study of LM-350 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have an advanced solid tumor that has not responded to standard treatments, or you cannot tolerate them.
- You can provide a tumor sample from a recent biopsy (within 3 years) or be willing to have a biopsy.
- You must have at least one tumor that can be measured on a scan.
- You cannot have cancer that has spread to your brain or spinal cord, or a history of certain bowel or heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug, LM-364, given alone or with other cancer treatments for people with advanced solid tumors. It aims to see if the drug is safe and effective.
This study tests a new drug called LM-299 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if LM-299 is safe and effective.
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
This trial tests a new drug, ML-016, for people with advanced solid tumors that have spread to the lungs or liver and haven't responded to standard treatments. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Hear when a new Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.